microRNA: A Molecular Window into Brain Injury

MicroRNAs (miRNAs) are short non-coding RNA molecules, typically 18–25 nucleotides in length, that regulate gene expression throughout the body. They are found in virtually all human cells and play important roles in cellular development, stress response, and tissue-specific function. Following cellular injury or death — including the neuronal and glial cell damage that occurs in TBI — intracellular miRNAs can be released into the extracellular space and enter the bloodstream. Their relative stability in blood (protected by encapsulation in exosomes and protein complexes) makes them candidates for blood-based biomarkers of tissue injury.

Protein biomarkers such as GFAP (Glial Fibrillary Acidic Protein) and UCH-L1 (Ubiquitin C-terminal Hydrolase-L1) are well-established in TBI research and have achieved regulatory clearance for acute mTBI assessment in adults. They measure specific structural proteins released from injured brain cells. MicroRNAs are nucleic acids rather than proteins, and they regulate gene expression rather than serving a structural function. Because miRNAs and proteins reflect different aspects of cellular biology, a panel approach combining multiple miRNAs may provide complementary information to protein biomarkers — potentially extending the biological picture beyond the acute injury window. GLIA’s research is investigating this complementary role; it is not positioned as a replacement for established protein biomarkers.

MicroRNA biomarkers for TBI are an active area of international research, but they have not yet achieved the level of regulatory clearance that protein biomarkers such as GFAP and UCH-L1 have in some jurisdictions. GLIA Diagnostics has conducted human clinical studies and published peer-reviewed research demonstrating that specific circulating miRNAs show altered expression following TBI in sport, military, and civilian populations. However, GLIA’s platform remains investigational. Further analytical and clinical validation is required before any clinical diagnostic use. Readers should distinguish between published research findings and regulatory-cleared clinical tools.

Mild TBI (mTBI) and concussion are among the most diagnostically challenging conditions in medicine. CT and conventional MRI are frequently normal in mTBI, leaving clinicians reliant on symptom reporting and observational tools. GLIA’s research has investigated whether its miRNA panel can detect molecular signals in mTBI cases where imaging is normal. Preliminary findings suggest potential utility in this population, but these results require further prospective validation before any clinical conclusions can be drawn. GLIA’s platform is investigational and not approved for clinical diagnostic use.

Circulating miRNAs are relatively stable in blood compared to many other RNA species. This stability arises primarily from their encapsulation within exosomes (small membrane-bound vesicles) and their association with RNA-binding proteins and lipoprotein complexes, which protect them from degradation by RNases present in blood. Temporal profiles vary by the individual miRNA, injury characteristics, and sampling time. This stability is one of the properties that makes circulating miRNAs candidates for blood-based biomarkers, including in field or point-of-care settings where sample processing may be delayed.

No single biomarker — whether a protein or a miRNA — is likely to capture the full biological complexity of TBI. Brain injury involves multiple cell types (neurons, astrocytes, oligodendrocytes, microglia), multiple injury mechanisms (primary mechanical injury, secondary inflammatory and metabolic cascades), and a range of injury severities and locations. A panel of miRNAs, each potentially reflecting different aspects of the injury response, may provide more comprehensive biological information than any single marker. GLIA’s panel approach is designed to capture this complexity, though the specific clinical utility of the panel requires further validation.

One of the most clinically unmet needs in TBI management is objective monitoring of biological recovery — particularly for return-to-activity decisions in sport and military contexts. Current return-to-play and return-to-duty protocols rely heavily on symptom resolution, which does not necessarily reflect underlying biological recovery. GLIA’s longitudinal research has investigated whether serial miRNA measurements over time show temporal patterns relevant to biological recovery. Preliminary findings are promising, but validated recovery monitoring applications require further prospective clinical research. These applications remain under development.

Published research findings and a regulatory-cleared clinical diagnostic test are fundamentally different things. Research findings demonstrate that a biological signal exists and may be associated with a condition of interest — they do not establish that a test is safe, accurate, and reliable enough for clinical decision-making. Regulatory clearance (such as FDA 510(k) clearance in the US or TGA registration in Australia) requires extensive analytical validation, clinical validation across diverse populations, and demonstration of clinical utility. GLIA’s miRNA panel has published research support but is not yet regulatory-cleared. It should not be used for clinical diagnostic purposes.